Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with hemophilia A or B

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: August 2021

Workgroups: Blood Disorders and Blood Safety Workgroup

In this Cochrane systematic review, researchers found that preventive treatment with clotting factor concentrates may reduce the number of joint bleeds in people with hemophilia who have previously been treated for joint bleeding. This may lead to an improvement in joint function, pain, and quality of life. However, further research is needed to determine the best starting time, frequency, and dose of preventive treatment.

Read more about this resource

Objectives related to this resource (1)

Reduce the proportion of people with severe hemophilia who have more than 4 joint bleeds each year — BDBS‑01
Target met or exceeded

Suggested Citation

1.

Olasupo, O. O., Lowe, M. S., Krishan, A., Collins, P., Iorio, A. & Matino, D. (2021). Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B, 2021 (8). DOI: 10.1002/14651858.CD014201.